Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 1/20 | 0.48 |
| ▸ | CD274 | Q9NZQ7 | 6/20 | 0.45 |
| ▸ | PDCD1 | Q15116 | 5/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 4/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | CCR3 | P51677 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16812719 | 0.92 | SMO (0.52) | SMOCD274PDCD1CHRM4DRD4 | |
| SCHEMBL18286582 | 0.92 | CHRM4 (0.50) | SMOCD274PDCD1CHRM4CHRM2 | |
| SCHEMBL16812721 | 0.92 | SMO (0.48) | SMOCD274CHRM4CHRM2CHRM1 | |
| SCHEMBL16812722 | 0.92 | SMO (0.48) | SMOCD274CHRM4CHRM2CHRM1 | |
| SCHEMBL16812729 | 0.92 | SMO (0.46) | SMOCD274PDCD1CHRM4CHRM2 | |
| SCHEMBL16811795 | 0.88 | SMO (0.55) | SMOCD274PDCD1DRD4DRD3 | |
| SCHEMBL16812761 | 0.87 | SMO (0.69) | SMOCD274PDCD1CHRM4DRD4 | |
| SCHEMBL18286512 | 0.87 | SMO (0.53) | SMOCD274PDCD1DRD4MCHR1 | |
| SCHEMBL16812716 | 0.86 | SMO (0.51) | SMOCHRM4DRD4HTR2AMCHR1 | |
| SCHEMBL16812735 | 0.85 | SMO (0.52) | SMOCD274CHRM4DRD4HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150166509-A1 | SMOOTHENED MODULATORS AND METHODS OF USE THEREOF | UNIV DUKE (US) | 2015-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166509-A1 | SMOOTHENED MODULATORS AND METHODS OF USE THEREOF | SMO, SHH, GLI1 | SMO 1/4885CD274 4285/4885PDCD1 4160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.